PRTG (Portage Biotech) 3-Year Share Buyback Ratio : -17.90% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Portage Biotech 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Portage Biotech's current 3-Year Share Buyback Ratio was -17.90%.

The historical rank and industry rank for Portage Biotech's 3-Year Share Buyback Ratio or its related term are showing as below:

PRTG' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -122.4 Med: -33.1 Max: 70.8
Current: -17.9

During the past 13 years, Portage Biotech's highest 3-Year Share Buyback Ratio was 70.80%. The lowest was -122.40%. And the median was -33.10%.

PRTG's 3-Year Share Buyback Ratio is ranked worse than
63.3% of 1286 companies
in the Biotechnology industry
Industry Median: -10.35 vs PRTG: -17.90

Competitive Comparison of Portage Biotech's 3-Year Share Buyback Ratio

For the Biotechnology subindustry, Portage Biotech's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Portage Biotech's 3-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Portage Biotech's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Portage Biotech's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Portage Biotech 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Portage Biotech (NAS:PRTG) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Portage Biotech 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Portage Biotech's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Portage Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portage Biotech Inc (NAS:PRTG) » Definitions » 3-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Clarence Thomas Building, P.O. Box 4649, Tortola, Road Town, VGB, VG1110

Website

https://www.portagebiotech.com

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.